|
Observational cross-sectional study evaluating the sociodemographic and clinical characteristics of patients with metastatic melanoma harboring a BRAF V600 mutation, treated with cobimetinib and vemurafenib based on routine clinical practice. |
|
Maria Carmen Álamo de la Gala |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Roche; Sanofi |
Speakers' Bureau - Eisai; EUSA Pharma; Merck; MSD; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
Juana Maria Oramas Rodriguez |
No Relationships to Disclose |
|
|
Expert Testimony - Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Roche |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche |
|
Fernando Garicano Goldaraz |
Honoraria - Amgen; Bristol-Myers Squibb; MSD |
Consulting or Advisory Role - Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim |
Speakers' Bureau - Leo Pharma; Novartis; Roche; ROVI |
|
|
|
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novarre Biologistics |